During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Yasushi Miyazaki, Nagasaki University, Nagasaki, JP. Here, Yasushi Miyazaki discusses the key take-home messages from the ASTRAL-1 study.
Yasushi Miyazaki discusses the results of the ASTRAL-1 study, which examined the efficacy of guadecitabine in patients with AML. He summarizes the study design and patient outcomes of this study. He concludes by stating that the judiciously prolonged use of guadecitabine can be beneficial to patients with AML.